Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes

SAN DIEGO & REHOVOT, Israel, April 04, 2024--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes. The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10

Related Keywords

Israel ,United States ,Texas ,San Diego ,California ,American ,Jake Robison ,Mathias Ehrich ,University Of Texas Md Anderson Cancer Center ,Nucleix Ltd ,American Association For Cancer Research ,American Association ,Cancer Research ,Annual Meeting ,Cancer Center ,Epigenetic Targets ,Poster Number ,The Company ,Small Cell Lung Cancer ,Cancer Treatment ,Racr ,Clc ,Pcr Assay ,Liquid Biopsy ,Poster Presentation ,Na Methylation ,